|
VTI1A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.44249065417534E-15 |
| Normal-vs-Stage2 |
8.05159999783811E-08 |
| Normal-vs-Stage3 |
8.88178419700125E-16 |
| Normal-vs-Stage4 |
1.62636570877339E-12 |
| Stage1-vs-Stage2 |
4.915200E-01 |
| Stage1-vs-Stage3 |
1.094370E-01 |
| Stage1-vs-Stage4 |
1.711950E-02 |
| Stage2-vs-Stage3 |
9.453900E-02 |
| Stage2-vs-Stage4 |
1.818500E-02 |
| Stage3-vs-Stage4 |
2.732000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.30040000004372E-06 |
| Normal-vs-Asian |
2.68369770850541E-11 |
| Caucasian-vs-AfricanAmerican |
3.822400E-01 |
| Caucasian-vs-Asian |
9.020800E-01 |
| AfricanAmerican-vs-Asian |
4.801800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.55111512312578E-16 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
2.302200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.64623870091418E-12 |
| Normal-vs-Age(41-60Yrs) |
1.99840144432528E-15 |
| Normal-vs-Age(61-80Yrs) |
1.79034564951053E-12 |
| Normal-vs-Age(81-100Yrs) |
1.456660E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.472200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.114400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.113000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.865000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.081600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.032200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.576500E-02 |
| Classical-VS-Follicular |
5.694400E-01 |
| Classical-VS-Other |
2.302400E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.988450E-02 |
| Tall-VS-Other |
8.928400E-01 |
| Tall-VS-Normal |
4.56856774633252E-12 |
| Follicular-VS-Other |
2.801000E-01 |
| Follicular-VS-Normal |
1.81949999511488E-08 |
| Other-VS-Normal |
3.7944000000012E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.09134923320653E-13 |
| Normal-vs-N1 |
3.77475828372553E-15 |
| N0-vs-N1 |
1.114130E-02 |
|
|
